scholarly journals How Far Are We from Prescribing Fasting as Anticancer Medicine?

2020 ◽  
Vol 21 (23) ◽  
pp. 9175
Author(s):  
Maria V. Deligiorgi ◽  
Charis Liapi ◽  
Dimitrios T. Trafalis
Keyword(s):  
Cellular Response ◽  
Clinical Evidence ◽  
Randomized Clinical Trials ◽  
Future Perspectives ◽  
Differential Stress ◽  
Normal Cells ◽  
Safety And Efficacy ◽  
Fasting And Refeeding ◽  
Personalized Approach ◽  
Potential Exploitation

(1) Background: the present review provides a comprehensive and up-to date overview of the potential exploitation of fasting as an anticancer strategy. The rationale for this concept is that fasting elicits a differential stress response in the setting of unfavorable conditions, empowering the survival of normal cells, while killing cancer cells. (2) Methods: the present narrative review presents the basic aspects of the hormonal, molecular, and cellular response to fasting, focusing on the interrelationship of fasting with oxidative stress. It also presents nonclinical and clinical evidence concerning the implementation of fasting as adjuvant to chemotherapy, highlighting current challenges and future perspectives. (3) Results: there is ample nonclinical evidence indicating that fasting can mitigate the toxicity of chemotherapy and/or increase the efficacy of chemotherapy. The relevant clinical research is encouraging, albeit still in its infancy. The path forward for implementing fasting in oncology is a personalized approach, entailing counteraction of current challenges, including: (i) patient selection; (ii) fasting patterns; (iii) timeline of fasting and refeeding; (iv) validation of biomarkers for assessment of fasting; and (v) establishment of protocols for patients’ monitoring. (4) Conclusion: prescribing fasting as anticancer medicine may not be far away if large randomized clinical trials consolidate its safety and efficacy.

scholarly journals Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion

2012 ◽  
Vol 4 ◽  
pp. OED.S7264
Author(s):  
Roberto Gallego-Pinazo ◽  
Rosa Dolz-Marco ◽  
Cristina Marín-Lambíes ◽  
Manuel Díaz-Llopis
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
San Francisco ◽  
Laser Photocoagulation ◽  
Clinical Evidence ◽  
Randomized Clinical Trials ◽  
Intravitreal Triamcinolone ◽  
Safety And Efficacy ◽  
Vein Occlusion ◽  
Retinal Vein Occlusions

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

Recent Advances in Computational Methods for Identifying Anticancer Peptides

2019 ◽  
Vol 20 (5) ◽  
pp. 481-487 ◽  
Author(s):  
Pengmian Feng ◽  
Zhenyi Wang
Keyword(s):  
Computational Methods ◽  
Clinical Applications ◽  
Future Perspectives ◽  
Small Peptides ◽  
Accurate Identification ◽  
Normal Cells ◽  
Anticancer Peptide ◽  
Anticancer Peptides ◽  
Computational Identification ◽  
Reliable Methods

Anticancer peptide (ACP) is a kind of small peptides that can kill cancer cells without damaging normal cells. In recent years, ACP has been pre-clinically used for cancer treatment. Therefore, accurate identification of ACPs will promote their clinical applications. In contrast to labor-intensive experimental techniques, a series of computational methods have been proposed for identifying ACPs. In this review, we briefly summarized the current progress in computational identification of ACPs. The challenges and future perspectives in developing reliable methods for identification of ACPs were also discussed. We anticipate that this review could provide novel insights into future researches on anticancer peptides.

scholarly journals Titanium oral implants: surface characteristics, interface biology and clinical outcome

2010 ◽  
Vol 7 (suppl_5) ◽  
Author(s):  
Anders Palmquist ◽  
Omar M. Omar ◽  
Marco Esposito ◽  
Jukka Lausmaa ◽  
Peter Thomsen
Keyword(s):  
Surface Properties ◽  
Cellular Response ◽  
Randomized Clinical Trials ◽  
Three Dimensional ◽  
Cell Communication ◽  
Surface Characteristics ◽  
Titanium Implants ◽  
Material Surface ◽  
Oral Implants

Bone-anchored titanium implants have revolutionized oral healthcare. Surface properties of oral titanium implants play decisive roles for molecular interactions, cellular response and bone regeneration. Nevertheless, the role of specific surface properties, such as chemical and phase composition and nanoscale features, for the biological in vivo performance remains to be established. Partly, this is due to limited transfer of state-of-the-art preparation techniques to complex three-dimensional geometries, analytical tools and access to minute, intact interfacial layers. As judged by the available results of a few randomized clinical trials, there is no evidence that any particular type of oral implant has superior long-term success. Important insights into the recruitment of mesenchymal stem cells, cell–cell communication at the interface and high-resolution imaging of the interface between the surface oxide and the biological host are prerequisites for the understanding of the mechanisms of osseointegration. Strategies for development of the next generation of material surface modifications for compromised tissue are likely to include time and functionally programmed properties, pharmacological modulation and incorporation of cellular components.

Abstract P476: Safety and Efficacy of Balloon Mounted Drug-Eluting Stent in the Treatment of Symptomatic Intracranial Atherosclerotic Disease Multicenter International Experience

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Mahmoud Mohammaden ◽  
Raul G Nogueira ◽  
WONDWOSSEN TEKLE ◽  
farhan siddiq ◽  
Diogo C Haussen ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Endovascular Treatment ◽  
Medical Management ◽  
Randomized Clinical Trials ◽  
Atherosclerotic Disease ◽  
Drug Eluting Stent ◽  
Safety And Efficacy ◽  
Intracranial Atherosclerotic Disease ◽  
Drug Eluting

Introduction: Intracranial atherosclerotic disease (ICAD) is a common cause of refractory stroke. Randomized clinical trials failed to prove the safety and efficacy of the endovascular treatment options of symptomatic ICAD (sICAD). However, there are many concerns regarding inclusion criteria in these trials which made them less effective than standard medical management. Herein, we aim to study the safety and efficacy of drug-eluting balloon mounted stents (DES) in the treatment of sICAD. Methods: A retrospective review of endovascular database from 10 comprehensive stroke centers inside and outside the USA from January 2017 to January 2020 was reviewed. Patients were included if they had symptomatic intracranial stenosis ≥70% in the target vessel, failed best medical management, and underwent intracranial stenting with DES. The primary outcome was the occurrence of ischemic stroke, hemorrhage, or mortality within 72 hours of the procedure. Secondary outcomes included rates of symptomatic and angiographic recurrence within 6 months of the procedure. Results: There was a total of 129 patients, the median age was 65 [58-72] years, 40 (31%) were females. The intracranial stenotic lesions were located in anterior circulation in 74 (57.4%) of cases [24 (18.6%) supraclinoid ICA, 5 (3.9%) cavernous ICA, 17 (13.2%) petrous ICA, 5 (19.4%) MCA-M1, and 3 (2.3%) M2] and in posterior circulation in 55 (42.6%) of cases [36 (27.9) vertebral artery V4 segment, 18 (14%) basilar and 1 (0.7%) PCA]. Recurrent stroke was the qualifying event in 101 (78.3%) while transient ischemic attacks (TIA) were identified in 28 (21.7%) of cases. The median time from the qualifying event to stenting was 6 [2-24] days. Strokes were reported within 72 hours of the procedure; 2 (1.6%) ischemic, 2 (1.6%) hemorrhagic strokes and 2 (1.6%) patients suffered inpatient mortality. The median follow-up time was 6 [3-6.75] months. Among 99 patients who had clinical follow up 2 (2%) had TIA and 6 (6.1%) had strokes. Fifty-one patients had follow-up imaging of whom symptomatic ISR was reported in 8 (15.7%). Conclusion: Our study has shown that in appropriately selected patients with sICAD, endovascular treatment using DES is safe and effective. Prospective randomized clinical trials are warranted.

scholarly journals Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the Benefits?

2020 ◽  
Vol 6 ◽  
Author(s):  
Oren Caspi ◽  
Doron Aronson
Keyword(s):  
Heart Failure ◽  
Adverse Event ◽  
Acute Heart Failure ◽  
Observational Studies ◽  
Retrospective Studies ◽  
Acute Pulmonary Oedema ◽  
Physiological Effects ◽  
Future Perspectives ◽  
Safety And Efficacy ◽  
Clinical Benefits

The use of opioids in acute pulmonary oedema is considered standard therapy by many physicians. The immediate relieving effect of morphine on the key symptomatic discomfort associated with acute heart failure, dyspnoea, facilitated the categorisation of morphine as a beneficial treatment in this setting. During the last decade, several retrospective studies raised concerns regarding the safety and efficacy of morphine in the setting of acute heart failure. In this article, the physiological effects of morphine on the cardiovascular and respiratory systems are summarised, as well as the potential clinical benefits and risks associated with morphine therapy. Finally, the reported clinical outcomes and adverse event profiles from recent observational studies are discussed, as well as future perspectives and potential alternatives to morphine in the setting of acute heart failure.

Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials

2018 ◽  
Vol 56 (10) ◽  
pp. 1110-1119 ◽  
Author(s):  
Yazan Zayed ◽  
Babikir Kheiri ◽  
Momen Banifadel ◽  
Michael Hicks ◽  
Ahmed Aburahma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Uncontrolled Asthma ◽  
Safety And Efficacy

Bronchiale Thermoplastie bei Asthmapatienten mit schwerer Obstruktion: Benefit und Komplikationsrisiko

2020 ◽  
Vol 8 (1) ◽  
pp. 24-25
Author(s):  
Lars Hagmeyer
Keyword(s):  
Adverse Event ◽  
Treatment Efficacy ◽  
Randomized Clinical Trials ◽  
Medication Use ◽  
Adverse Outcomes ◽  
Similar Degree ◽  
Asthma Control Questionnaire ◽  
Safety And Efficacy ◽  
Reliever Medication ◽  
Oral Steroids

Background: Randomized clinical trials of bronchial thermoplasty (BT) were conducted in patients with a baseline FEV1 greater than 50%. There is a paucity of data regarding BT in patients with more severe obstruction, and consequently these patients are often excluded from receiving BT. The purpose of this study was to compare safety and efficacy outcomes in a large cohort of patients with an FEV1 less than 50% with those of a cohort of less obstructed patients. Methods: Consecutive patients with severe asthma were drawn from the Australian BT Registry. Patients were grouped into (1) those with a baseline prebronchodilator FEV1 % predicted <50% (n = 32) or (2) those with an FEV1 ≥50% (n = 36). Adverse outcomes were defined as (1) remaining in hospital longer than the planned 24-hour admission posttreatment or (2) being readmitted to hospital for any cause within 30 days of a treatment. Efficacy outcomes were evaluated 6 months after BT. Results: More severely obstructed patients were no more likely to have experienced any adverse event. Significant improvements in Asthma Control Questionnaire score, exacerbation frequency, reliever medication use, and requirement for daily oral steroids were observed in both groups, and were of a similar degree. Conclusions: This study demonstrates that BT can confidently be offered to patients with asthma with an FEV1 that is 30% to 50% of predicted without risk of more frequent or more severe adverse events, and with the expectation of the same degree of response as patients with better lung function.

Androgen-Deprivation Therapy in Prostate Cancer: Clinical Evidence and Future Perspectives

2010 ◽  
Vol 77 (2) ◽  
pp. 71-83
Author(s):  
F. Pinto ◽  
A. Calamo ◽  
A. Totaro ◽  
E. Sacco ◽  
A. Volpe ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Clinical Evidence ◽  
Androgen Deprivation ◽  
Future Perspectives
Sign in / Sign up

Export Citation Format

Share Document